Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

95
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
95
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

82
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
82
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

67
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
67
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

57
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
57
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.6K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19.

Critical care explorations·2026
Same author

Fluid Management of Acute Heart Failure With the Reprieve System: The Randomized Controlled FASTR Trial.

JACC. Heart failure·2026
Same author

Label free multimodal optical imaging of metabolic heterogeneity in aging by integrating SRS, MPF, FLIM, and SHG.

bioRxiv : the preprint server for biology·2026
Same author

RACGAP1 as a Circulating Biomarker of Atrial Fibrillation in Heart Failure: A Dual-Cohort Proteomic Study.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Therapeutic scheduling of WEE1 inhibition preserves T cell function and promotes immune control of HPV<sup>+</sup> tumors.

bioRxiv : the preprint server for biology·2026
Same author

STAR Power: Noninvasive Radiation Therapy for Ventricular Tachycardia Enters a New Era.

International journal of radiation oncology, biology, physics·2026

Related Experiment Video

Updated: Sep 28, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

HDL Composition, Heart Failure, and Its Comorbidities.

Ahmed Diab1, Carla Valenzuela Ripoll1, Zhen Guo1

  • 1Division of Cardiology, Washington University School of Medicine, Saint Louis, MO, United States.

Frontiers in Cardiovascular Medicine
|March 30, 2022
PubMed
Summary

High-density lipoprotein (HDL) shows promise for treating heart failure, offering antioxidant and anti-inflammatory benefits. HDL-associated proteins may protect the heart by influencing signaling pathways and sphingosine-1-phosphate biology.

Keywords:
apolipoprotein A-Iapolipoprotein Mcardiomyopathyheart failurehigh-density lipoprotein (HDL)sphingosine-1-phosphate

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.7K
Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

28.1K

Related Experiment Videos

Last Updated: Sep 28, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.7K
Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

28.1K

Area of Science:

  • Cardiovascular Research
  • Lipid Metabolism
  • Heart Failure Pathophysiology

Background:

  • Historically, high-density lipoprotein (HDL) research centered on atherosclerotic coronary disease.
  • Emerging evidence suggests HDL biology has untapped potential for heart failure (HF) treatment.
  • HF is a complex syndrome involving comorbidities and intricate lipoprotein interactions.

Purpose of the Study:

  • To review the impact of heart failure and comorbidities on HDL.
  • To explore the cardioprotective properties of HDL in heart failure.
  • To identify novel HDL therapeutic targets for heart failure.

Main Methods:

  • Literature review focusing on HDL biology and heart failure.
  • Analysis of HDL's antioxidant, anti-inflammatory, and endothelial protective functions.
  • Examination of HDL-associated proteins (e.g., apolipoprotein A-I, M) and their myocardial effects.

Main Results:

  • HDL possesses antioxidant, anti-inflammatory, and endothelial protective properties relevant to HF pathogenesis.
  • HDL-associated proteins may exert therapeutic effects on the myocardium.
  • Complex interactions exist between HF, comorbidities, and lipoprotein homeostasis.

Conclusions:

  • HDL biology offers promising therapeutic avenues for heart failure.
  • Targeting HDL and its associated proteins could represent a novel strategy for HF treatment.
  • Further research is warranted to elucidate HDL's role and therapeutic potential in heart failure.